Medicare

Medical Device Companies Support MDUFA VI Agreement, While Patients Call for Stronger Post-Market Safety

The latest agreement to fund medical device fees in the United States enjoys broad industry support, but patient groups are calling for expanded use of real-world evidence to monitor devices after they reach the market. The agreement includes higher fees for foreign companies, greater transparency regarding staffing at the medical device division, and the conversion of the TAP program into a permanent program.